Citation

Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ, Gispen-de Wied CC, Ruis JR, Elferink AJ, Storosum JG. Eur. Neuropsychopharmacol. 2005; 16(2): 79-83.

Affiliation

Medicenes Evaluation Board of the Netherlands, P.O. Box 16229, 2500 BE The Hague, The Netherlands.

Copyright

(Copyright © 2005, Elsevier Publishing)

DOI

10.1016/j.euroneuro.2005.10.004

PMID

16298514

Abstract

OBJECTIVE: Antidepressants use in pediatric patients has been linked with risk of suicidal behaviours. The aim of this paper, therefore, is to examine whether all antidepressants are associated with such risk. METHOD: All 22 pediatric short-term placebo-controlled trials of SSRIs and NSRIs that were submitted to European registration authorities by pharmaceutical companies were identified and examined for events related to suicidality, which were defined as suicide, suicide attempts or suicidal thoughts. Random effect meta-analysis was used to combine the information from all trials. RESULTS: No completed suicides were reported. However, for each compound there was at least one study with an increased risk for events related to suicidality in the active compound group. The overall OR for these events in the depression studies was 1.67 (95% CI: 1.05-2.65) and for anxiety 1.33 (95% CI: 0.33-5.35). CONCLUSIONS: Caution is called for in the use of all SSRIs and NSRIs in the pediatric population. Furthermore, in the absence of contradictory information, caution in the use of other antidepressants in this population should be exercised as well (e.g. tricyclic antidepressants).